MigVax has developed a vaccine against avian Coronavirus and Infectious Bronchitis Virus (IBV) which can be administered orally. The COVID-19 vaccine project was initiated given the high similarity COVID-19 has with IBV and avian Coronavirus and are working towards genetic adjustments to develop an effective vaccine towards COVID-19. Oral administration increases safety, efficiency and are cost-effective in large scale manufacturing.
Required for the website to work, for example security features and remembering your cookie choices. These cannot be switched off.
Help us understand how visitors use the website so we can improve it.
Used to show relevant ads and measure their effectiveness, and by embedded content such as videos and maps from other websites.